Article Sidebar
Published:
Jan 26, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Identification of key bioactive anti-migraine constituents of <i>Asari radix</i> et rhizoma using network pharmacology and nitroglycerin-induced migraine rat model
Abstract
Purpose: To elucidate the bioactive constituents of Asari radix et rhizoma (ARR) in treating migraine based on network pharmacology and nitroglycerin-induced migraine rat model.
Methods: The potential bioactive constituents of ARR were identified with the aid of literature retrieval and virtual screening, and the migraine-related hub genes were identified using protein-protein interaction and topology analyses. Then, the interaction between the potential bioactive constituents and hub genes was determined with molecular docking and topology, leading to the prediction of the anti-migraine constituents of ARR. Moreover, a rat model of nitroglycerin-induced migraine was used to confirm the prediction by measuring the frequency of head-scratching and head-shaking behavior (FHHB) in the rats. In addition, levels of nitric oxide (NO) and calcitonin gene-related peptide (CGRP) in blood, norepinephrine (NE) and 5-hydroxytryptamine (5-HT) in brain were measured using appropriate commercial kits.
Results: Network pharmacology revealed that naringenin-7-O-β-D-glucopyranoside and higenamine might be the key anti-migraine bioactive constituents of ARR. On addition of naringenin-7-O-β-D- glucopyranoside or higenamine to ARR, there was marked enhancement of the mitigating effect of ARR on nitroglycerin-induced abnormalities in levels of NO, CGRP, 5-HT and NE, as well as FHHB in rats (p < 0.05 or 0.01).
Conclusion: These findings indicate that naringenin-7-O-β-D-glucopyranoside and higenamine might be the key bioactive and anti-migraine constituents of ARR. However, in addition to naringenin-7-O-β-D- glucopyranoside and higenamine, there were many other anti-migraine constituents in ARR. Therefore, there is need for further investigations on the actual contributions of these two constituents of ARR in treating migraine.
